Ecalta®
(anidulafungin)

What is Ecalta and what is it used for?

Ecalta contains the active substance anidulafungin and is prescribed in adults and children (aged 1 month to 18 years) to treat a type of fungal infection of the blood or other internal organs called invasive candidiasis. The infection is caused by fungal cells (yeasts) called Candida.

Ecalta belongs to a group of medicines called echinocandins. These medicines are used to treat serious fungal infections.

Ecalta prevents normal development of fungal cell walls. In the presence of Ecalta , fungal cells have incomplete or defective cell walls, making them fragile or unable to grow.

Ecalta can only be obtained with a prescription and should only be taken under the supervision of a doctor.

 

Reference information

Medicines in Northern Ireland fall under the remit of the European Medicines Agency (EMA) whilst medicines in Great Britain (England, Scotland and Wales) fall under the remit of the Medicines and Healthcare products Regulatory Agency (MHRA) following the UK leaving the European Union. These agencies are responsible for the scientific evaluation, supervision and safety monitoring of medicines developed by pharmaceutical companies.

If you would like to see the Summary of Product Characteristics (SPC) or Patient Information Leaflet (PIL) for Ecalta please follow these links:


Great Britain
Ecalta (anidulafungin)

Northern Ireland
Ecalta (anidulafungin)

 

Pfizer is unable to provide advice on personal medical matters. Please consult your doctor or other relevant health professional for specific, health-related advice and support.

If you get any side effects when taking this or any other medicine, talk to your doctor or other relevant health professional e.g. pharmacist, nurse. This includes any possible side effects not listed in the packaging leaflet. You can also report side effects directly via the Yellow Card Scheme at https://yellowcard.mhra.gov.uk or search the Google Play or Apple App Store for MHRA Yellow Card. By reporting side effects, you can help provide more information on the safety of this medicine.

  PP-ECA-GBR-0025 / October 2021